ES2358528T3 - Vitamina k para la prevención y el tratamiento de una erupción cutánea secundaria a una terapia anti-egfr. - Google Patents
Vitamina k para la prevención y el tratamiento de una erupción cutánea secundaria a una terapia anti-egfr. Download PDFInfo
- Publication number
- ES2358528T3 ES2358528T3 ES06750246T ES06750246T ES2358528T3 ES 2358528 T3 ES2358528 T3 ES 2358528T3 ES 06750246 T ES06750246 T ES 06750246T ES 06750246 T ES06750246 T ES 06750246T ES 2358528 T3 ES2358528 T3 ES 2358528T3
- Authority
- ES
- Spain
- Prior art keywords
- vitamin
- egfr
- skin
- therapy
- formulated
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 201000005884 exanthem Diseases 0.000 title claims abstract description 36
- MBWXNTAXLNYFJB-NKFFZRIASA-N phylloquinone Chemical compound C1=CC=C2C(=O)C(C/C=C(C)/CCC[C@H](C)CCC[C@H](C)CCCC(C)C)=C(C)C(=O)C2=C1 MBWXNTAXLNYFJB-NKFFZRIASA-N 0.000 title claims description 48
- 238000011282 treatment Methods 0.000 title claims description 25
- 238000011123 anti-EGFR therapy Methods 0.000 title claims description 12
- 230000002265 prevention Effects 0.000 title claims description 7
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 claims abstract description 66
- 208000010201 Exanthema Diseases 0.000 claims abstract description 34
- 206010037844 rash Diseases 0.000 claims abstract description 34
- 231100000046 skin rash Toxicity 0.000 claims abstract description 21
- 238000000034 method Methods 0.000 claims abstract description 20
- 238000002560 therapeutic procedure Methods 0.000 claims abstract description 19
- 239000000203 mixture Substances 0.000 claims abstract description 18
- 229940116977 epidermal growth factor Drugs 0.000 claims abstract description 15
- 102000009465 Growth Factor Receptors Human genes 0.000 claims abstract description 7
- 108010009202 Growth Factor Receptors Proteins 0.000 claims abstract description 7
- MJVAVZPDRWSRRC-UHFFFAOYSA-N Menadione Chemical compound C1=CC=C2C(=O)C(C)=CC(=O)C2=C1 MJVAVZPDRWSRRC-UHFFFAOYSA-N 0.000 claims description 208
- 235000012711 vitamin K3 Nutrition 0.000 claims description 90
- 239000011652 vitamin K3 Substances 0.000 claims description 90
- 102000001301 EGF receptor Human genes 0.000 claims description 74
- 108060006698 EGF receptor Proteins 0.000 claims description 74
- ABSPRNADVQNDOU-UHFFFAOYSA-N Menaquinone 1 Natural products C1=CC=C2C(=O)C(CC=C(C)C)=C(C)C(=O)C2=C1 ABSPRNADVQNDOU-UHFFFAOYSA-N 0.000 claims description 47
- 235000019175 phylloquinone Nutrition 0.000 claims description 47
- 239000011772 phylloquinone Substances 0.000 claims description 47
- 229960001898 phytomenadione Drugs 0.000 claims description 47
- 239000008194 pharmaceutical composition Substances 0.000 claims description 11
- 238000009472 formulation Methods 0.000 claims description 10
- 238000011200 topical administration Methods 0.000 claims description 10
- 229940121647 egfr inhibitor Drugs 0.000 claims description 7
- 229960005395 cetuximab Drugs 0.000 claims description 6
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical group C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 claims description 6
- 238000013268 sustained release Methods 0.000 claims description 5
- 239000012730 sustained-release form Substances 0.000 claims description 5
- 239000005411 L01XE02 - Gefitinib Substances 0.000 claims description 4
- 229960002584 gefitinib Drugs 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 229930003448 Vitamin K Natural products 0.000 abstract description 19
- 235000019168 vitamin K Nutrition 0.000 abstract description 19
- 239000011712 vitamin K Substances 0.000 abstract description 19
- 229940046010 vitamin k Drugs 0.000 abstract description 19
- 150000003721 vitamin K derivatives Chemical class 0.000 abstract description 18
- 229940122907 Phosphatase inhibitor Drugs 0.000 abstract description 2
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 abstract 1
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 abstract 1
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 43
- 210000003491 skin Anatomy 0.000 description 37
- 230000000694 effects Effects 0.000 description 23
- 239000005551 L01XE03 - Erlotinib Substances 0.000 description 20
- 229960001433 erlotinib Drugs 0.000 description 18
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 description 17
- 210000001519 tissue Anatomy 0.000 description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
- 230000005764 inhibitory process Effects 0.000 description 11
- 230000026731 phosphorylation Effects 0.000 description 10
- 238000006366 phosphorylation reaction Methods 0.000 description 10
- 241000699666 Mus <mouse, genus> Species 0.000 description 9
- 230000004913 activation Effects 0.000 description 9
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 9
- 102000009024 Epidermal Growth Factor Human genes 0.000 description 8
- 101800003838 Epidermal growth factor Proteins 0.000 description 8
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 8
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 8
- 239000003795 chemical substances by application Substances 0.000 description 8
- 241000699670 Mus sp. Species 0.000 description 7
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 6
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 239000006071 cream Substances 0.000 description 6
- 230000003834 intracellular effect Effects 0.000 description 6
- -1 phos-EGFR Proteins 0.000 description 6
- 230000002441 reversible effect Effects 0.000 description 6
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 description 6
- 239000005483 tyrosine kinase inhibitor Substances 0.000 description 6
- 229940088594 vitamin Drugs 0.000 description 6
- 229930003231 vitamin Natural products 0.000 description 6
- 235000013343 vitamin Nutrition 0.000 description 6
- 239000011782 vitamin Substances 0.000 description 6
- PFRQBZFETXBLTP-UHFFFAOYSA-N Vitamin K2 Natural products C1=CC=C2C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C(=O)C2=C1 PFRQBZFETXBLTP-UHFFFAOYSA-N 0.000 description 5
- 235000019441 ethanol Nutrition 0.000 description 5
- 239000000284 extract Substances 0.000 description 5
- 238000003119 immunoblot Methods 0.000 description 5
- DKHGMERMDICWDU-GHDNBGIDSA-N menaquinone-4 Chemical compound C1=CC=C2C(=O)C(C/C=C(C)/CC/C=C(C)/CC/C=C(C)/CCC=C(C)C)=C(C)C(=O)C2=C1 DKHGMERMDICWDU-GHDNBGIDSA-N 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 235000019143 vitamin K2 Nutrition 0.000 description 5
- 239000011728 vitamin K2 Substances 0.000 description 5
- 229940041603 vitamin k 3 Drugs 0.000 description 5
- 239000003112 inhibitor Substances 0.000 description 4
- 230000000699 topical effect Effects 0.000 description 4
- ZKHQWZAMYRWXGA-KQYNXXCUSA-N Adenosine triphosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-N 0.000 description 3
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 3
- 201000004624 Dermatitis Diseases 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 206010047741 Vulval cancer Diseases 0.000 description 3
- 229960001456 adenosine triphosphate Drugs 0.000 description 3
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000012139 lysis buffer Substances 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 239000002953 phosphate buffered saline Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 210000004881 tumor cell Anatomy 0.000 description 3
- 201000004916 vulva carcinoma Diseases 0.000 description 3
- 208000013013 vulvar carcinoma Diseases 0.000 description 3
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- XZKIHKMTEMTJQX-UHFFFAOYSA-N 4-Nitrophenyl Phosphate Chemical compound OP(O)(=O)OC1=CC=C([N+]([O-])=O)C=C1 XZKIHKMTEMTJQX-UHFFFAOYSA-N 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 108091054455 MAP kinase family Proteins 0.000 description 2
- 102000043136 MAP kinase family Human genes 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 201000010989 colorectal carcinoma Diseases 0.000 description 2
- 239000002537 cosmetic Substances 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- VIYFPAMJCJLZKD-UHFFFAOYSA-L disodium;(4-nitrophenyl) phosphate Chemical compound [Na+].[Na+].[O-][N+](=O)C1=CC=C(OP([O-])([O-])=O)C=C1 VIYFPAMJCJLZKD-UHFFFAOYSA-L 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 229940082789 erbitux Drugs 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 201000003911 head and neck carcinoma Diseases 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 229940084651 iressa Drugs 0.000 description 2
- 239000006166 lysate Substances 0.000 description 2
- 230000003211 malignant effect Effects 0.000 description 2
- 231100000682 maximum tolerated dose Toxicity 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 2
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 208000017520 skin disease Diseases 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 229940120982 tarceva Drugs 0.000 description 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 2
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 2
- DYLIWHYUXAJDOJ-OWOJBTEDSA-N (e)-4-(6-aminopurin-9-yl)but-2-en-1-ol Chemical compound NC1=NC=NC2=C1N=CN2C\C=C\CO DYLIWHYUXAJDOJ-OWOJBTEDSA-N 0.000 description 1
- FRASJONUBLZVQX-UHFFFAOYSA-N 1,4-naphthoquinone Chemical compound C1=CC=C2C(=O)C=CC(=O)C2=C1 FRASJONUBLZVQX-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 208000003322 Coinfection Diseases 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- RRHGJUQNOFWUDK-UHFFFAOYSA-N Isoprene Chemical compound CC(=C)C=C RRHGJUQNOFWUDK-UHFFFAOYSA-N 0.000 description 1
- 229930192627 Naphthoquinone Natural products 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 102000002727 Protein Tyrosine Phosphatase Human genes 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 101710140204 Signal transducer and transcription activator Proteins 0.000 description 1
- 206010059516 Skin toxicity Diseases 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 238000005842 biochemical reaction Methods 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 230000007012 clinical effect Effects 0.000 description 1
- 239000008278 cosmetic cream Substances 0.000 description 1
- 238000000326 densiometry Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- UKHVLWKBNNSRRR-ODZAUARKSA-M dowicil 200 Chemical compound [Cl-].C1N(C2)CN3CN2C[N+]1(C\C=C/Cl)C3 UKHVLWKBNNSRRR-ODZAUARKSA-M 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 208000021045 exocrine pancreatic carcinoma Diseases 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 108091006086 inhibitor proteins Proteins 0.000 description 1
- 230000031146 intracellular signal transduction Effects 0.000 description 1
- 230000004068 intracellular signaling Effects 0.000 description 1
- 229940074928 isopropyl myristate Drugs 0.000 description 1
- XUGNVMKQXJXZCD-UHFFFAOYSA-N isopropyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC(C)C XUGNVMKQXJXZCD-UHFFFAOYSA-N 0.000 description 1
- 229940075495 isopropyl palmitate Drugs 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 238000013532 laser treatment Methods 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 150000002791 naphthoquinones Chemical class 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 238000003616 phosphatase activity assay Methods 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- DCWXELXMIBXGTH-UHFFFAOYSA-N phosphotyrosine Chemical compound OC(=O)C(N)CC1=CC=C(OP(O)(O)=O)C=C1 DCWXELXMIBXGTH-UHFFFAOYSA-N 0.000 description 1
- 229920001992 poloxamer 407 Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 229940126731 protein tyrosine phosphatase inhibitor Drugs 0.000 description 1
- 239000003806 protein tyrosine phosphatase inhibitor Substances 0.000 description 1
- 108020000494 protein-tyrosine phosphatase Proteins 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 210000003079 salivary gland Anatomy 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 229920002545 silicone oil Polymers 0.000 description 1
- 239000002884 skin cream Substances 0.000 description 1
- 231100000438 skin toxicity Toxicity 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 102000035160 transmembrane proteins Human genes 0.000 description 1
- 108091005703 transmembrane proteins Proteins 0.000 description 1
- PZYFJWVGRGEWGO-UHFFFAOYSA-N trisodium;hydrogen peroxide;trioxido(oxo)vanadium Chemical compound [Na+].[Na+].[Na+].OO.OO.OO.[O-][V]([O-])([O-])=O PZYFJWVGRGEWGO-UHFFFAOYSA-N 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US67156305P | 2005-04-15 | 2005-04-15 | |
| US671563P | 2005-04-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2358528T3 true ES2358528T3 (es) | 2011-05-11 |
Family
ID=37115750
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES06750246T Active ES2358528T3 (es) | 2005-04-15 | 2006-04-12 | Vitamina k para la prevención y el tratamiento de una erupción cutánea secundaria a una terapia anti-egfr. |
Country Status (13)
| Country | Link |
|---|---|
| US (4) | US7745494B2 (enExample) |
| EP (3) | EP1871353B1 (enExample) |
| JP (2) | JP2008536865A (enExample) |
| KR (1) | KR101332869B1 (enExample) |
| AT (1) | ATE492275T1 (enExample) |
| AU (1) | AU2006236633B2 (enExample) |
| CA (2) | CA2851079A1 (enExample) |
| CY (1) | CY1111786T1 (enExample) |
| DE (1) | DE602006019074D1 (enExample) |
| DK (1) | DK1871353T3 (enExample) |
| ES (1) | ES2358528T3 (enExample) |
| PT (1) | PT1871353E (enExample) |
| WO (1) | WO2006113479A2 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7595378B2 (en) | 2001-06-13 | 2009-09-29 | Genmab A/S | Human monoclonal antibodies to epidermal growth factor receptor (EGFR) |
| CA2851079A1 (en) | 2005-04-15 | 2006-10-26 | Albert Einstein College Of Medicine Of Yeshiva University | Vitamin k for prevention and treatment of skin rash secondary to anti-egfr therapy |
| EP2043685B1 (en) * | 2006-07-03 | 2015-12-23 | Genmab A/S | Prevention of rash in patients undergoing anti-egfr therapy |
| US8815953B2 (en) * | 2008-03-13 | 2014-08-26 | Spectrum Pharmaceuticals, Inc. | Formulations of vitamin K analogs for topical use |
| US20100010100A1 (en) * | 2008-07-09 | 2010-01-14 | Hinman Andrew W | Dermatological compositions with anti-aging and skin even-toning properties |
| US20100029784A1 (en) * | 2008-07-30 | 2010-02-04 | Hinman Andrew W | Naphthoquinone compositions with anti-aging, anti-inflammatory and skin even-toning properties |
| JP5765634B2 (ja) | 2008-10-21 | 2015-08-19 | スレッシュホールド ファーマシューティカルズ， インコーポレイテッド | 低酸素活性化型プロドラッグを用いるがんの処置 |
| CN102458473A (zh) * | 2009-06-26 | 2012-05-16 | 英属开曼群岛商安盛开发药物股份有限公司 | 治疗或减缓粘膜皮肤或眼睛毒性的方法 |
| ITPD20100090A1 (it) * | 2010-03-22 | 2011-09-23 | Sanitas Farmaceutici S R L | Formulazione topica per il trattamento di eruzioni cutanee, in particolare conseguenti a trattamenti con farmaci anti egfr |
| WO2012111187A1 (ja) | 2011-02-14 | 2012-08-23 | 株式会社Ｊ－オイルミルズ | 皮膚コラーゲン産生促進剤 |
| EP2712613B1 (en) * | 2012-09-28 | 2017-02-08 | Pharmadab d.o.o. | Vitamin K1 and uses thereof |
| US9421297B2 (en) | 2014-04-02 | 2016-08-23 | Adhezion Biomedical, Llc | Sterilized compositions of cyanoacrylate monomers and naphthoquinone 2,3-oxides |
| WO2016120341A2 (en) | 2015-01-27 | 2016-08-04 | Vitak B.V. | Epidermal skin health |
| CN111601617A (zh) | 2017-12-13 | 2020-08-28 | 上海岸阔医药科技有限公司 | 一种用于预防或治疗与egfr 被抑制相关疾病的方法 |
| JP7520366B2 (ja) | 2018-04-16 | 2024-07-23 | オンクオリティー ファーマシューティカルズ チャイナ リミテッド | 腫瘍療法の副作用の予防または治療方法 |
Family Cites Families (87)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA84119A (en) | 1903-11-06 | 1903-12-01 | Edward M. Haymaker | Cover and strainer for milk pails |
| CA91784A (en) | 1904-10-05 | 1905-02-28 | William Stevenson | Dining and billiard table |
| US3155031A (en) | 1962-03-16 | 1964-11-03 | Babco Products Inc | Printing and digital coding machine |
| US4294852A (en) | 1973-11-01 | 1981-10-13 | Johnson & Johnson | Skin treating compositions |
| EP0015436B1 (de) | 1979-03-08 | 1982-02-03 | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft | Verfahren zur stereospezifischen Herstellung von Verbindungen der Vitamin K1- und K2-Reihe sowie neue Ausgangsprodukte in diesem Verfahren |
| JPS6025918A (ja) | 1983-07-25 | 1985-02-08 | Ajinomoto Co Inc | 脂溶性薬物含有水性液 |
| DE3406497A1 (de) | 1984-02-23 | 1985-09-05 | Mueller Bernhard Willi Werner | Hochdisperse pharmazeutische mehrkomponentensysteme und verfahren zu ihrer herstellung |
| DE3514724A1 (de) | 1985-04-24 | 1986-10-30 | Albin F. Dr. 4200 Oberhausen Jereb | Salbe zur verbeugung und behandlung von augen- und hauterkrankungen |
| JPS62294636A (ja) | 1986-05-21 | 1987-12-22 | Eisai Co Ltd | ２−メチル−１，４−ナフトキノンの製造法 |
| US5180747A (en) | 1989-02-28 | 1993-01-19 | Nisshin Flour Milling Co., Ltd. | Stabilized fat-soluble vitamin compositions |
| ZA902066B (en) | 1989-04-14 | 1990-12-28 | Minnesota Mining & Mfg | Solid gel external drug delivery system |
| US4966779A (en) | 1989-12-21 | 1990-10-30 | Basf Corporation | Stable, water miscible emulsion comprising a fat-soluble vitamin |
| US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
| KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
| US5155031A (en) | 1990-06-07 | 1992-10-13 | Posner Barry I | Use of pervanadate as an inhibitor of phosphotyrosine phosphatase |
| FR2672288B1 (fr) | 1991-02-06 | 1993-04-23 | Oreal | Nouveaux amides dipeptidiques derivant de la glycyl-serine, utilisables, notamment dans des compositions cosmetiques, pharmaceutiques ou alimentaires. |
| DE4141351A1 (de) | 1991-12-14 | 1993-06-17 | Basf Ag | Stabile pulverfoermige vitamin- und/oder carotinoid-praeparate und verfahren zu deren herstellung |
| US5650156A (en) | 1993-02-22 | 1997-07-22 | Vivorx Pharmaceuticals, Inc. | Methods for in vivo delivery of nutriceuticals and compositions useful therefor |
| US6537579B1 (en) | 1993-02-22 | 2003-03-25 | American Bioscience, Inc. | Compositions and methods for administration of pharmacologically active compounds |
| US5785976A (en) | 1993-03-05 | 1998-07-28 | Pharmacia & Upjohn Ab | Solid lipid particles, particles of bioactive agents and methods for the manufacture and use thereof |
| US5885486A (en) | 1993-03-05 | 1999-03-23 | Pharmaciaand Upjohn Ab | Solid lipid particles, particles of bioactive agents and methods for the manufacture and use thereof |
| US5643765A (en) | 1993-04-06 | 1997-07-01 | University Of Rochester | Method for quantitative measurement of gene expression using multiplex competitive reverse transcriptase-polymerase chain reaction |
| CA2117412A1 (en) | 1993-07-26 | 1995-01-27 | Eisai Co., Ltd. | Preparation process of naphthoquinone derivative and intermediate for the preparation thereof |
| US5510391A (en) | 1993-10-22 | 1996-04-23 | Mayapple Holdings, Llc | Method of treating blood vessel disorders of the skin using vitamin K |
| FR2719219B1 (fr) | 1994-05-02 | 1996-06-21 | Rocher Yves Biolog Vegetale | Composition cosmétique ou pharmaceutique à usage topique comprenant des vésicules lipidiques. |
| US5637741A (en) | 1994-09-27 | 1997-06-10 | Kuraray Co., Ltd. | Process for producing 2-methyl-1,4-naphthoquinone |
| JPH09143042A (ja) * | 1995-11-24 | 1997-06-03 | Lion Corp | 口腔用組成物 |
| WO1997039746A1 (en) * | 1996-04-22 | 1997-10-30 | Advanced Polymer Systems, Inc. | Method of and composition for treating disorders of the skin using vitamin k |
| KR0178456B1 (ko) | 1996-04-25 | 1999-05-15 | 김흥기 | 2-메틸-1,4-나프토퀴논(비타민 k3)의 제조방법 |
| SE9601665D0 (sv) | 1996-04-30 | 1996-04-30 | Bioglan Ab | Biologically active composition |
| US6110891A (en) | 1996-06-21 | 2000-08-29 | Alizyme Therapeutics Ltd. | Lectin compositions and uses thereof |
| DE19642359A1 (de) | 1996-10-14 | 1998-04-16 | Basf Ag | Stabile Emulsionen und Trockenpulver von Mischungen fettlöslicher Vitamine, deren Herstellung und Verwendung |
| US5916749A (en) | 1996-12-13 | 1999-06-29 | Incyte Pharmaceuticals, Inc. | Human phosphatase inhibitor protein |
| US6426078B1 (en) | 1997-03-17 | 2002-07-30 | Roche Vitamins Inc. | Oil in water microemulsion |
| US6372234B1 (en) | 1997-05-27 | 2002-04-16 | Sembiosys Genetics Inc. | Products for topical applications comprising oil bodies |
| US6599513B2 (en) | 1997-05-27 | 2003-07-29 | Sembiosys Genetics Inc. | Products for topical applications comprising oil bodies |
| KR20010031501A (ko) | 1997-10-31 | 2001-04-16 | 추후제출 | 5-알파 환원효소 활성을 조절하는 방법 및 조성물 |
| US6696484B2 (en) | 1997-10-31 | 2004-02-24 | University Of Chicago Office Of Technology And Intellectual Property | Method and compositions for regulation of 5-alpha reductase activity |
| US6013665A (en) | 1997-12-16 | 2000-01-11 | Abbott Laboratories | Method for enhancing the absorption and transport of lipid soluble compounds using structured glycerides |
| AU4438399A (en) * | 1998-06-11 | 1999-12-30 | University Of Medicine And Dentistry Of New Jersey | Wound treatment through inhibition of adenosine diphosphate ribosyl transferase |
| US6207176B1 (en) | 1998-09-14 | 2001-03-27 | National Starch And Chemical Investment Holding Corporation | Starch based adhesives for skin cleaning tape |
| US6383471B1 (en) | 1999-04-06 | 2002-05-07 | Lipocine, Inc. | Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents |
| US6187822B1 (en) | 1999-06-11 | 2001-02-13 | University Of Medicine & Dentistry Of Nj | Wound treatment through inhibition of adenosine diphosphate ribosyl transferase |
| US6524594B1 (en) | 1999-06-23 | 2003-02-25 | Johnson & Johnson Consumer Companies, Inc. | Foaming oil gel compositions |
| US7927612B2 (en) | 2000-01-19 | 2011-04-19 | Baofa Yu | Combinations and methods for treating neoplasms |
| DE10003786A1 (de) | 2000-01-28 | 2001-08-02 | Merck Patent Gmbh | Galenische Formulierung |
| US8883856B2 (en) | 2000-02-28 | 2014-11-11 | John Jackson | Compositions and methods for the treatment of inflammatory diseases using topoisomerase inhibitors |
| US20030185877A1 (en) * | 2000-03-17 | 2003-10-02 | Roland Betz | Method of producing oily suspensions of water-soluble vitamins |
| WO2001070255A2 (en) * | 2000-03-20 | 2001-09-27 | Pfizer Products, Inc. | Combined treatment with keratinocyte growth factor and epidermal growth factor inhibitor |
| US20040047852A1 (en) | 2001-03-02 | 2004-03-11 | Kennedy Thomas Preston | Method of treating cancer |
| US20020040011A1 (en) | 2000-06-01 | 2002-04-04 | Brown Dennis M. | Naphthoquinone compositions and uses thereof |
| PL342071A1 (en) | 2000-08-18 | 2001-02-12 | Szolomicka Orfinger Irena | Cosmetic cream |
| GB0022079D0 (en) * | 2000-09-08 | 2000-10-25 | Inst Of Molecul & Cell Biology | Novel protein tyrosine phosphatase inhibitor |
| US6660306B2 (en) | 2000-10-12 | 2003-12-09 | Mickey L. Peshoff | Wound healing compound |
| US7094431B2 (en) * | 2000-10-12 | 2006-08-22 | Mickey L. Peshoff | Method of healing skin wounds in mammals and a composition therefor |
| US6774100B2 (en) | 2000-12-06 | 2004-08-10 | Imaginative Research Associates, Inc. | Anhydrous creams, lotions and gels |
| US7604812B2 (en) | 2000-12-15 | 2009-10-20 | Patrick Franke | Hypoallergenic and non-irritant skin care formulations |
| EP1214930B1 (en) | 2000-12-15 | 2004-03-31 | Patrick Dr. Franke | Hypoallergenic and non-irritant skin care formulations |
| US6780439B2 (en) * | 2001-03-06 | 2004-08-24 | J. Ronald Wilk | Wound treatment solution and method for using same |
| US6579994B2 (en) | 2001-03-29 | 2003-06-17 | Council Of Scientific And Industrial Research | Process for preparation of 2-Methyl-1,4-naphthoquinone |
| AU2002361550A1 (en) * | 2001-07-20 | 2003-04-22 | Human Genome Sciences, Inc. | Keratinocyte derived interferon |
| US20070238697A1 (en) | 2001-08-29 | 2007-10-11 | University Of British Columbia | Pharmaceutical compositions and methods relating to fucans |
| US6812220B2 (en) | 2001-08-29 | 2004-11-02 | University Of British Columbia | Pharmaceutical compositions and methods relating to fucans |
| US8156471B2 (en) | 2001-11-09 | 2012-04-10 | Oracle International Corporation | Multi-language execution method |
| US7405188B2 (en) | 2001-12-12 | 2008-07-29 | Wsp Chemicals & Technology, Llc | Polymeric gel system and compositions for treating keratin substrates containing same |
| WO2003061566A2 (en) | 2002-01-24 | 2003-07-31 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Anti-cancer combination and use thereof |
| JP2003226639A (ja) | 2002-01-31 | 2003-08-12 | Hisamitsu Pharmaceut Co Inc | 神経成長因子活性増強剤としてのビタミンｋ類を含む医薬組成物およびその使用 |
| US20030170187A1 (en) | 2002-03-01 | 2003-09-11 | Alfred Marchal | Skin treatments containing nano-sized vitamin K |
| GB0212749D0 (en) | 2002-06-01 | 2002-07-10 | Boots Co Plc | Personal care compositions |
| GB0220182D0 (en) | 2002-08-30 | 2002-10-09 | Cardiovascular Res Inst Maastr | Organic compounds |
| US7326690B2 (en) | 2002-10-30 | 2008-02-05 | Bach Pharma, Inc. | Modulation of cell fates and activities by phthalazinediones |
| AU2003230980A1 (en) | 2003-04-18 | 2004-11-26 | Northeastern University | Micelle delivery system loaded with a pharmaceutical agent |
| JP2005020651A (ja) | 2003-06-30 | 2005-01-20 | Hitachi Ltd | タイムスタンプ情報検証方法 |
| US7320797B2 (en) | 2003-08-29 | 2008-01-22 | Bioderm Research | Antiaging cosmetic delivery systems |
| CA2533887A1 (en) | 2003-09-30 | 2005-04-14 | Acusphere, Inc. | Injectable, oral, or topical sustained release pharmaceutical formulations |
| US20050092969A1 (en) | 2003-10-08 | 2005-05-05 | Kaneka Corporation | Method of stabilizing compound having quinone skeleton and stabilized composition |
| JP2005206521A (ja) | 2004-01-22 | 2005-08-04 | Nippon Menaade Keshohin Kk | 抗菌剤 |
| KR20060002239A (ko) | 2004-07-01 | 2006-01-09 | 삼성전자주식회사 | 레이저 출력 제어장치 |
| EP1796656A2 (en) | 2004-09-17 | 2007-06-20 | Oystershell NV | Composition for inhibiting or preventing the formation of a biofilm |
| US20090010887A1 (en) | 2004-10-06 | 2009-01-08 | Ben-Sasson Shmuel A | Method and composition for enhancing anti-angiogenic therapy |
| WO2006107827A1 (en) | 2005-04-05 | 2006-10-12 | Creighton University | Skin bonding process |
| CA2851079A1 (en) | 2005-04-15 | 2006-10-26 | Albert Einstein College Of Medicine Of Yeshiva University | Vitamin k for prevention and treatment of skin rash secondary to anti-egfr therapy |
| US20060275504A1 (en) | 2005-06-07 | 2006-12-07 | Tty Biopharm Company Limited | Methods and compositions for augmenting cancer chemotherapeutic agents |
| US20070025950A1 (en) | 2005-07-28 | 2007-02-01 | Elson Melvin L | Composition and method for treating cellulite |
| US7252816B1 (en) | 2006-03-29 | 2007-08-07 | Dow Pharmaceutical Sciences | Topical acne vulgairs medication with a sunscreen |
| WO2007147128A2 (en) | 2006-06-16 | 2007-12-21 | Summa Health System | Non-toxic anti-cancer drug combining ascorbate, magnesium and a naphthoquinone |
| ES2414708T3 (es) | 2006-07-07 | 2013-07-22 | Tiltan Pharma Ltd | Tratamiento anticanceroso que comprende un bloqueante de H2, al menos un agente antiinflamatorio y un agente citotóxico |
-
2006
- 2006-04-12 CA CA2851079A patent/CA2851079A1/en not_active Abandoned
- 2006-04-12 EP EP06750246A patent/EP1871353B1/en active Active
- 2006-04-12 KR KR1020077026480A patent/KR101332869B1/ko not_active Expired - Fee Related
- 2006-04-12 ES ES06750246T patent/ES2358528T3/es active Active
- 2006-04-12 AU AU2006236633A patent/AU2006236633B2/en not_active Ceased
- 2006-04-12 EP EP10195772.8A patent/EP2305224B1/en active Active
- 2006-04-12 DK DK06750246.8T patent/DK1871353T3/da active
- 2006-04-12 AT AT06750246T patent/ATE492275T1/de active
- 2006-04-12 WO PCT/US2006/014158 patent/WO2006113479A2/en not_active Ceased
- 2006-04-12 EP EP11189225A patent/EP2494965A3/en not_active Withdrawn
- 2006-04-12 US US11/886,803 patent/US7745494B2/en not_active Expired - Fee Related
- 2006-04-12 DE DE602006019074T patent/DE602006019074D1/de active Active
- 2006-04-12 PT PT06750246T patent/PT1871353E/pt unknown
- 2006-04-12 JP JP2008506765A patent/JP2008536865A/ja not_active Withdrawn
- 2006-04-12 CA CA2603785A patent/CA2603785C/en not_active Expired - Fee Related
-
2009
- 2009-05-14 US US12/465,980 patent/US20090239952A1/en not_active Abandoned
-
2010
- 2010-05-26 US US12/788,015 patent/US8283382B2/en not_active Expired - Fee Related
-
2011
- 2011-03-16 CY CY20111100295T patent/CY1111786T1/el unknown
-
2012
- 2012-09-06 JP JP2012196249A patent/JP5620443B2/ja not_active Expired - Fee Related
- 2012-09-20 US US13/623,625 patent/US20130225690A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CA2603785C (en) | 2014-07-22 |
| EP2305224A2 (en) | 2011-04-06 |
| CY1111786T1 (el) | 2015-10-07 |
| EP2305224B1 (en) | 2015-03-11 |
| EP1871353A2 (en) | 2008-01-02 |
| AU2006236633A1 (en) | 2006-10-26 |
| KR101332869B1 (ko) | 2013-11-25 |
| JP2012236857A (ja) | 2012-12-06 |
| DK1871353T3 (da) | 2011-04-04 |
| HK1111920A1 (en) | 2008-11-07 |
| EP1871353A4 (en) | 2009-06-24 |
| US20090209652A1 (en) | 2009-08-20 |
| CA2603785A1 (en) | 2006-10-26 |
| AU2006236633B2 (en) | 2012-03-29 |
| JP5620443B2 (ja) | 2014-11-05 |
| US7745494B2 (en) | 2010-06-29 |
| US20090239952A1 (en) | 2009-09-24 |
| WO2006113479A3 (en) | 2007-05-10 |
| EP2494965A2 (en) | 2012-09-05 |
| US20100324148A1 (en) | 2010-12-23 |
| ATE492275T1 (de) | 2011-01-15 |
| EP2494965A3 (en) | 2013-01-02 |
| EP1871353B1 (en) | 2010-12-22 |
| CA2851079A1 (en) | 2006-10-26 |
| PT1871353E (pt) | 2011-03-29 |
| WO2006113479A2 (en) | 2006-10-26 |
| KR20070121843A (ko) | 2007-12-27 |
| US8283382B2 (en) | 2012-10-09 |
| EP2305224A3 (en) | 2011-12-14 |
| DE602006019074D1 (de) | 2011-02-03 |
| JP2008536865A (ja) | 2008-09-11 |
| US20130225690A1 (en) | 2013-08-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8283382B2 (en) | Vitamin K for prevention and treatment of skin rash secondary to anti-EGFR therapy | |
| Marko et al. | Inhibition of cyclin-dependent kinase 1 (CDK1) by indirubin derivatives in human tumour cells | |
| US20120258060A1 (en) | Methods for protecting the skin from radiation insults | |
| CA2995605C (en) | Transdermal formulations for delivery of berberine compounds, and their use in the treatment of berberine-responsive diseases and conditions | |
| Shi et al. | Bilobalide prevents apoptosis through activation of the PI3K/Akt pathway in SH-SY5Y cells | |
| CA2641308A1 (en) | Use of phosphatases to treat tumors overexpressing n-cor | |
| EP3730144A1 (en) | Agent for treatment of nervous system disease | |
| Chang et al. | Prodigiosin inhibits gp91phox and iNOS expression to protect mice against the oxidative/nitrosative brain injury induced by hypoxia–ischemia | |
| ES3026632T3 (en) | Compounds for use in the treatment and prevention of covid- 19 | |
| US20170340689A1 (en) | Titrated extracts of cynara scolymus for use in the treatment of mesothelioma | |
| Wu et al. | Research progress in small molecules as anti-vitiligo agents | |
| KR102470557B1 (ko) | 아플리쿠로딘 a를 유효성분으로 포함하는 암 예방, 개선 또는 치료용 조성물 | |
| JP6644479B2 (ja) | がん治療のための併用療法としてのエリブリンとｓ−１（もしくは５−ｆｕ）の使用 | |
| HK1111920B (en) | Vitamin k for prevention and treatment of skin rash secondary to anti-egfr therapy | |
| HK1153125A (en) | Vitamin k analog for treatment of skin or mucosal ulceration | |
| HK1175691A (en) | Vitamin k for prevention and treatment of skin rash secondary to anti-egfr therapy | |
| AU2012201344A1 (en) | Vitamin K for prevention and treatment of skin rash secondary to anti-EGFR therapy | |
| EP3651770B1 (en) | Theacrine-based supplement and method of use thereof in a synergistic combination with caffeine | |
| US20240066017A1 (en) | Prevention or treatment of brain disease and adverse effects of cholinesterase inhibitors | |
| Hegazy et al. | Modulation of monoamines and amino-acids neurotransmitters in cerebral cortex and hippocampus of female senile rats by ginger and lipoic acid | |
| KR20250173014A (ko) | 카로티노이드를 포함하는 근육 질환의 예방 및 치료용 약학 조성물 | |
| CN114159427A (zh) | 一种包含安卓幸醇的组合物用于制备抑制肝癌细胞或肝癌干细胞生长的药物的用途 |